Related Experiment Video
Updated: Jan 17, 2026

O-Ring Aortic Banding Versus Traditional Transverse Aortic Constriction for Modeling Pressure Overload-Induced Cardiac Hypertrophy
Published on: October 6, 2022
Clinical Outcomes Post-Transcatheter Aortic Valve Replacement in Patients With Hypertrophic Obstructive
Muhammad Usman Almani1, Vibhor Ahluwalia2, Muhammad Yousuf3
1Division of Cardiology, Jefferson Einstein Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Insights
Transcatheter aortic valve replacement (TAVR) in patients with hypertrophic obstructive cardiomyopathy (HOCM) is associated with a significantly higher risk of in-hospital mortality. However, readmission outcomes were similar between HOCM and non-HOCM patients post-TAVR.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) patients were historically excluded from transcatheter aortic valve replacement (TAVR) trials.
- Post-TAVR "suicide left ventricle" is a concern due to potential worsening of left ventricular outflow tract obstruction.
Purpose of the Study:
- To evaluate clinical and readmission outcomes for HOCM patients undergoing TAVR.
- To compare outcomes between TAVR patients with and without comorbid HOCM.
Main Methods:
- Utilized data from the National Inpatient and National Readmission Databases (2016-2020).
- Performed multivariable logistic regression for in-hospital mortality and clinical outcomes.
- Employed multivariable Cox regression for 30-day readmission assessment.
Main Results:
- Identified 534 HOCM patients (0.2%) among 296,670 TAVR cases.
- HOCM patients had a >3-fold increased risk of in-hospital mortality (aOR: 3.47).
- HOCM patients experienced higher rates of atrioventricular blocks, cardiogenic shock, acute kidney injury, and intubation; no difference in readmissions.
Conclusions:
- TAVR in HOCM patients is linked to significantly higher in-hospital mortality.
- Patients with HOCM face increased procedural complications during TAVR.
- Real-world data indicates elevated risks for HOCM patients undergoing TAVR.
Background:
Patients with hypertrophic obstructive cardiomyopathy (HOCM) were excluded from all major trials for transcatheter aortic valve replacement (TAVR). "Suicide left ventricle" occurring after TAVR is postulated to occur as a result of chronic pressure overload from fixed obstruction that is acutely relieved after the valve deployment resulting in worsening left ventricular outflow tract obstruction.
Aims:
The aim of this study was to determine the clinical and readmission outcomes in HOCM patients undergoing TAVR.
Methods:
Data was extracted from the National Inpatient and National Readmission 2016-2020 Databases. We performed multivariable Logistic regression analysis to determine the odds of in-hospital mortality and other relevant clinical outcomes in patients undergoing TAVR with and without comorbid HOCM. Multivariable Cox regression analysis was used to assess 30-day hospital readmission in HOCM patients undergoing TAVR.
Results:
We identified 296,670 patients who underwent TAVR, of whom 534 (0.2%) had comorbid HOCM. The patients undergoing TAVR with comorbid HOCM had more than threefold higher risk of in-hospital mortality (adjusted odds ratio: 3.47, 95% CI 1.37-8.81, p = 0.009) when compared to patients without HOCM. Additionally, patients undergoing TAVR with comorbid HOCM had a higher risk of atrioventricular blocks, cardiogenic shock, acute kidney injury, and the need for intubation. There was no difference in readmission outcomes post-TAVR among patients with and without HOCM.
Conclusion:
Our analysis of a large, real-world cohort of patients undergoing TAVR showed that patients with HOCM have a significantly higher risk of in-hospital mortality and procedural complications when compared to patients without HOCM.
Related Concept Videos
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Aortic Regurgitation III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology

